

A Phase 1 Combination Study of ¹⁷⁷Lu POCUVOTIDE Satetraxetan and Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer

CellBion Co., Ltd
CellBion

ONCOLOGY

Phase 1

Product Type	RPT
Indication	Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Target	PD-1 (Programmed Cell Death Protein 1) & PSMA (Prostate-Specific Membrane Antigen)
MoA(Mechanism of Action)	PSMA-targeted radioligand therapy (RLT) may convert immunologically “cold” tumors into “hot” tumors by increasing immune infiltration and activity, thereby enhancing the efficacy of immune checkpoint inhibitors such as Pembrolizumab. This combination may significantly improve prostate cancer treatment outcomes.
Competitiveness	• Pluvicto became a blockbuster mCRPC treatment within three years of launch. • Current best-in-class strategies for mCRPC focus on expanding the eligible patient population through improved efficacy and safety profiles. • Combination therapy is emerging as a key strategy to enhance efficacy, and Cellbion is a first mover in combining radioligand therapy (RLT) with immune checkpoint modulation.
Development Stage	Phase 1
Route of Administration	Intravenous injection (i.v.)

Any unauthorized distribution or reproduction of this material is strictly prohibited.